Risk factor
Very vulnerable to price shocks
Profitability factor
Greatly undervalued vs peers
About
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima,...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap'
Target Price
The average target price of OGN is 9.4 and suggests 30% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell